Quantum Genomics Société Anonyme (QNNTF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.65 Million USD | -81.74% |
| 2022 | 20.01 Million EUR | 52.09% |
| 2021 | 13.15 Million USD | 31.97% |
| 2020 | 9.96 Million USD | 134.97% |
| 2019 | 4.24 Million EUR | -33.43% |
| 2018 | 6.37 Million USD | 40.38% |
| 2017 | 4.54 Million USD | 58.43% |
| 2016 | 2.86 Million USD | 47.32% |
| 2015 | 1.94 Million USD | -61.31% |
| 2014 | 5.02 Million USD | 31.9% |
| 2013 | 3.81 Million USD | 116.62% |
| 2012 | 1.75 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 3.31 Million EUR | -19.9% |
| 2023 Q4 | 3.31 Million EUR | 0.0% |
| 2023 FY | 3.65 Million USD | -81.74% |
| 2023 Q2 | 4.13 Million EUR | 0.0% |
| 2023 Q1 | 4.13 Million EUR | -79.35% |
| 2022 Q1 | 11.71 Million EUR | 1.24% |
| 2022 Q4 | 20.01 Million EUR | -0.2% |
| 2022 FY | 20.01 Million EUR | 52.09% |
| 2022 Q3 | 20.05 Million EUR | 71.11% |
| 2022 Q2 | 11.71 Million EUR | 0.0% |
| 2021 Q1 | 10.33 Million EUR | 26.82% |
| 2021 FY | 13.15 Million USD | 31.97% |
| 2021 Q4 | 11.57 Million EUR | 0.0% |
| 2021 Q3 | 11.57 Million EUR | 12.02% |
| 2021 Q2 | 10.33 Million EUR | 0.0% |
| 2020 Q1 | 8.16 Million EUR | 92.53% |
| 2020 Q2 | 8.16 Million EUR | 0.0% |
| 2020 Q4 | 8.14 Million EUR | 0.0% |
| 2020 FY | 9.96 Million USD | 134.97% |
| 2020 Q3 | 8.14 Million EUR | -0.19% |
| 2019 Q1 | 4.5 Million EUR | -19.13% |
| 2019 FY | 4.24 Million EUR | -33.43% |
| 2019 Q3 | 4.24 Million EUR | -5.96% |
| 2019 Q2 | 4.5 Million EUR | 0.0% |
| 2019 Q4 | 4.24 Million EUR | 0.0% |
| 2018 Q3 | 5.57 Million EUR | 8.98% |
| 2018 Q1 | 5.11 Million EUR | 35.4% |
| 2018 Q2 | 5.11 Million EUR | 0.0% |
| 2018 Q4 | 5.57 Million EUR | 0.0% |
| 2018 FY | 6.37 Million USD | 40.38% |
| 2017 Q2 | 2.66 Million EUR | 0.0% |
| 2017 FY | 4.54 Million USD | 58.43% |
| 2017 Q4 | 3.77 Million EUR | 0.0% |
| 2017 Q1 | 2.66 Million EUR | -1.89% |
| 2017 Q3 | 3.77 Million EUR | 41.82% |
| 2016 Q3 | 2.71 Million EUR | 33.83% |
| 2016 Q4 | 2.71 Million EUR | 0.0% |
| 2016 FY | 2.86 Million USD | 47.32% |
| 2016 Q2 | 2.02 Million EUR | 0.0% |
| 2016 Q1 | 2.02 Million EUR | 13.31% |
| 2015 Q3 | 1.79 Million EUR | 70.06% |
| 2015 FY | 1.94 Million USD | -61.31% |
| 2015 Q1 | 1.05 Million EUR | -74.66% |
| 2015 Q4 | 1.79 Million EUR | 0.0% |
| 2015 Q2 | 1.05 Million EUR | 0.0% |
| 2014 Q1 | 1.98 Million EUR | -40.15% |
| 2014 Q4 | 4.15 Million EUR | 0.0% |
| 2014 Q2 | 1.98 Million EUR | 0.0% |
| 2014 Q3 | 4.15 Million EUR | 109.04% |
| 2014 FY | 5.02 Million USD | 31.9% |
| 2013 Q3 | 3.32 Million EUR | 0.0% |
| 2013 FY | 3.81 Million USD | 116.62% |
| 2013 Q4 | 3.32 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2012 FY | 1.75 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 4.55% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.146% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 61.871% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -766.645% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.959% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.809% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 5.139% |
| Mesoblast Limited | 188.44 Million USD | 98.061% |
| Marizyme, Inc. | 26.67 Million USD | 86.304% |
| Genus plc | 485 Million USD | 99.247% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 37.468% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -45.192% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 3.855% |
| ContraFect Corporation | 32.53 Million USD | 88.769% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -84.398% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | 90.369% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 68.981% |
| MultiCell Technologies, Inc. | 1617.67 USD | -225749.339% |
| Accustem Sciences Inc. | 1.07 Million USD | -238.525% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.281% |
| EV Biologics, Inc. | 2.11 Million USD | -72.737% |
| Q BioMed Inc. | 8.13 Million USD | 55.078% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.595% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 29.004% |
| Biomind Labs Inc. | 1.49 Million USD | -143.792% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.148% |
| Skye Bioscience, Inc. | 14.07 Million USD | 74.038% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.699% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2471.165% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 61.404% |
| Intellipharmaceutics International Inc. | 12 Million USD | 69.576% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1716.612% |
| Neon Bloom, Inc. | 1.22 Million USD | -197.95% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.503% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -81.754% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 36.415% |
| GB Sciences, Inc. | 5.41 Million USD | 32.562% |
| Alpha Cognition Inc. | 7.16 Million USD | 49.008% |
| argenx SE | 444.95 Million USD | 99.179% |
| HST Global, Inc. | 593.59 Thousand USD | -515.489% |
| Halberd Corporation | 728.71 Thousand USD | -401.359% |
| Enzolytics Inc. | 365.26 Million USD | 99.0% |
| Resverlogix Corp. | 67.39 Million USD | 94.579% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -335.598% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.123% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.923% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -113.156% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 59.595% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.236% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -154.801% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 69.306% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 0.318% |
| AVAX Technologies, Inc. | 3.99 Million USD | 8.52% |
| ONE Bio Corp. | 27.49 Million USD | 86.713% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13152.193% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.724% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1430.876% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 2.164% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -436.621% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -34.734% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -190.146% |
| Agentix Corp. | 2.51 Million USD | -45.525% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 3.5 Million USD | -4.241% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5358.765% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.731% |
| BioStem Technologies, Inc. | 15.9 Million USD | 77.029% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -686.207% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13217.891% |
| LadRx Corporation | 2.2 Million USD | -66.028% |
| Cell Source, Inc. | 15.8 Million USD | 76.886% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8074.103% |
| Regen BioPharma, Inc. | 5.45 Million USD | 33.057% |
| Regen BioPharma, Inc. | 5.45 Million USD | 33.057% |
| NovAccess Global Inc. | 7.86 Million USD | 53.522% |
| Affymax, Inc. | 8.87 Million USD | 58.815% |
| Itoco Inc. | 1.65 Million USD | -121.002% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -78.083% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 39.602% |
| CytoDyn Inc. | 127.89 Million USD | 97.143% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8640.633% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -133.245% |
| Qrons Inc. | 1.48 Million USD | -145.413% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 66.923% |
| SYBLEU INC | 681.41 Thousand USD | -436.165% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -351.722% |
| Rebus Holdings, Inc. | 5.24 Million USD | 30.303% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 40.125% |
| Mobile Lads Corp. | 1.31 Million USD | -178.15% |
| International Stem Cell Corporation | 5.27 Million USD | 30.766% |
| Bioxytran, Inc. | 3.24 Million USD | -12.433% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -483.804% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 20.871% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.088% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.591% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -80.385% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 33.306% |
| Neutra Corp. | 973.52 Thousand USD | -275.284% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.408% |
| PureTech Health plc | 125.58 Million USD | 97.091% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 2.758% |
| IXICO plc | 1.9 Million USD | -92.26% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.203% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.464% |
| CSL Limited | 18.62 Billion USD | 99.98% |
| Cellectis S.A. | 249.36 Million USD | 98.535% |